Bamboo Therapeutics and CureDuchenne to Host a Webinar on Developing Gene Therapy for Duchenne Muscular Dystrophy on June 13, 2016
NEWPORT BEACH, Calif.–(BUSINESS WIRE)–#Bamboo—Bamboo
Therapeutics, Inc., a recently formed biotechnology company focused
on advancing therapies for rare pediatric diseases of the central and
neuromuscular systems, and CureDuchenne,
a nonprofit organization dedicated to funding research and improving
patient care for Duchenne muscular dystrophy, will host a webinar
“Bamboo Therapeutics – Developing a novel gene therapy for patients with
Duchenne Muscular Dystrophy” on Monday, June 13 at 3 p.m. ET/noon PT.
Speakers include:
-
Sharon Hesterlee, Ph.D., EVP Patient Advocacy and Public Affairs,
Bamboo Therapeutics -
Jude Samulski, Ph.D., Scientific Founder, Bamboo Therapeutics, and
former Director of the Gene Therapy Center at the University of North
Carolina -
Jak Knowles, MD, Vice President Medical and Scientific Affairs,
CureDuchenne, and Managing Director CureDuchenne Ventures - Debra Miller, Founder and CEO, CureDuchenne
During the webinar, Dr. Hesterlee and Dr. Samulski will discuss the
basics of gene therapy and a description of Bamboo’s approach to
developing a treatment for Duchenne muscular dystrophy; a gene therapy
utilizing a disabled virus to deliver a small, highly optimized version
of the dystrophin gene systemically to skeletal and cardiac muscle. The
gene therapy, originally called BMB-D001, has already shown positive
effects in Duchenne animal models, improving life span as well as
skeletal and cardiac muscle function in both mice and rats. Life
extension and maintenance of ambulation up to eight years post-treatment
resulted from long-term dystrophin production in a canine Duchenne
animal model.
CureDuchenne Ventures LLC, a venture philanthropy organization that
funds research to find a cure for Duchenne muscular dystrophy, provided
funding for Bamboo Therapeutics to help advance their gene therapy
treatment for Duchenne. This financial support will enable critical
pre-IND enabling studies to accelerate advancement of the therapy to
patient clinical trials.
Duchenne is a progressive muscle-wasting disease affecting more than
300,000 boys worldwide. Boys with Duchenne are usually diagnosed by the
age of 5, lose the ability to walk by age 12 and most don’t survive
their mid-20s. There is currently no approved treatment for Duchenne.
To register for the webinar on June 13, click here.
The call in number is 844-337-8088 and the conference ID number is
22853541.
About Bamboo Therapeutics, Inc.
Bamboo represents a community of researchers, clinicians, parents,
regulatory scientists, and business professionals committed to providing
hope to patients suffering from debilitating disease. Bamboo is focused
on some of the most devastating neurological and neuromuscular diseases
that affect children. Our lead therapeutic is a gene therapy product for
the treatment of Duchenne muscular dystrophy. Bamboo’s therapeutics are
derived from an exclusive rAAV platform technology, and are manufactured
using a proprietary scaled up process at an established GMP vector core
facility recently purchased by the company.
About CureDuchenne
CureDuchenne was founded in 2003 with a focus on saving the lives of
those with Duchenne muscular dystrophy. Affecting 1 in 3,500 boys,
Duchenne is the most common and lethal form of muscular dystrophy.
CureDuchenne has garnered international attention for its innovative
model of funding the most impactful research through venture
philanthropy and providing superior patient care through CureDuchenne
Cares. For additional information, please visit CureDuchenne.org
and follow us on Facebook,
Twitter
and YouTube.
Contacts
CureDuchenne
Karen Harley, (949) 872-2552
